Zenas BioPharma (ZBIO): Evaluating Valuation After Phase 2 MS Results and Major Funding Deal

Zenas BioPharma (ZBIO) is in the spotlight after announcing strong Phase 2 results for obexelimab in relapsing multiple sclerosis, the launch of key Phase 3 trials, and a major funding deal with Royalty Pharma.

See our latest analysis for Zenas BioPharma.

Zenas BioPharma's impressive 90-day share price return of 108.09% and an exceptional year-to-date gain of 288.46% point to surging investor optimism, propelled by breakthrough clinical results and major funding milestones. Short-term momentum has clearly shifted, reflecting rising confidence in the company’s growth outlook.

If Zenas’ recent rally has sparked your interest, consider exploring more healthcare innovators using our handpicked screener. See See the full list for free..

With shares already up sharply following breakthrough trial results and a major funding deal, the key question for investors is whether Zenas BioPharma remains undervalued or if the market has already factored in its future growth potential.

Price-to-Book of 9.6x: Is it justified?

With Zenas BioPharma trading at a price-to-book ratio of 9.6x and a last close price of $35.00, the stock commands a significant valuation premium compared to its peers.

The price-to-book ratio compares a company's market value to its book value, serving as a rough gauge for how highly investors rate its assets and prospects. In the biotech sector, higher ratios often reflect the market’s expectations for future growth, critical drug approvals, or strategic breakthroughs. For Zenas BioPharma, the elevated valuation signals strong confidence in its pipeline and future earnings potential.

This premium is much higher than the peer average of 4.1x and stands well above the US Biotechs industry average of 2.5x. The market is pricing in aggressive growth and significant breakthrough potential relative to similar companies, setting a high bar for future delivery.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 9.6x (OVERVALUED)

However, slower than expected revenue growth or persistent net losses could quickly challenge the optimism currently priced into Zenas BioPharma shares.

Find out about the key risks to this Zenas BioPharma narrative.

Build Your Own Zenas BioPharma Narrative

If you have a different take or would rather dig into the numbers yourself, you can build your own perspective in just minutes. Do it your way.

A great starting point for your Zenas BioPharma research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Don’t miss your chance to act on the next big trend. Our smart screeners offer exciting investment opportunities designed to match your ambitions and interests.

• Secure passive income streams as you check out these 16 dividend stocks with yields > 3% with yields higher than 3% and strong financial stability.
• Capitalize on advances in artificial intelligence by starting your journey with these 25 AI penny stocks as these companies are reshaping industries with new technology.
• Uncover hidden value and strengthen your portfolio using these 878 undervalued stocks based on cash flows which relies on robust cash flow analysis and fundamental metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com